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Objectives: To report (1) the incidence of post-attenuation seizures (PAS) in dogs that 74 
underwent single congenital extrahepatic portosystemic shunt (cEHPSS) attenuation and (2) 75 
to compare incidence of PAS in dogs that either did or did not receive prophylactic treatment 76 
with levetiracetam (LEV). 77 
Study Design: Multi-institutional retrospective study. 78 
Sample Population: Nine-hundred-and-forty dogs.  79 
Methods: Medical records were reviewed to identify dogs that underwent surgical 80 
attenuation of a single cEHPSS from January 2005 through July 2017 and developed PAS 81 
within seven days postoperatively. Dogs were divided into three groups: no LEV (LEV-); 82 
LEV at >15mg/kg TID for >24 hours or a 60mg/kg intravenous loading dose preoperatively, 83 
followed by >15mg/kg TID postoperatively (LEV1); and LEV at <15mg/kg TID, for <24 84 
hours preoperatively, or continued at <15mg/kg TID postoperatively (LEV2). 85 
Results: Nine-hundred-and-forty dogs were included. Seventy-five (8.0%) developed PAS. 86 
Incidence of PAS was 35/523 (6.7%), 21/188 (11.2%) and 19/228 (8.3%) in groups LEV-, 87 
LEV1 and LEV2, respectively. This difference was not statistically significant (p=0.14). No 88 
significant differences between groups of dogs that seized with respect to variables 89 
investigated were identified.  90 
Conclusions: The overall incidence of PAS was low (8%). Prophylactic treatment with LEV 91 
according to the protocols investigated in our study was not associated with a reduced 92 
incidence of PAS. 93 
Clinical Significance:  94 
Prophylactic treatment with LEV does not afford protection against development of PAS. 95 
Surgically treated dogs should continue to be monitored closely during the first seven days 96 
postoperatively for seizures.  97 
Introduction 98 
Development of post-attenuation seizures (PAS) is a devastating and frequently fatal 99 
postoperative complication in dogs undergoing surgical attenuation of congenital 100 
portosystemic shunts, with survival rates ranging from 0-53.8% in previous studies that 101 
included more than three affected dogs.1-7 Incidence of PAS has been reported as high as 102 
18.2%,1,2,4-8 and up to 4.7-8.1% in more recent literature.7,8 Seizures typically occur within 96 103 
hours postoperatively and have been reported following congenital extrahepatic- (cEHPSS)1-18 104 
and less commonly intrahepatic portosystemic shunt (cIHPSS) attenuation.13,14,19-25 Such 105 
seizures appear different to those observed preoperatively in that they are often very 106 
challenging to control, being refractory to typical first line anti-seizure medications.1-8,10-12,14-107 
16,21,22 108 
 109 
The etiopathogenesis of PAS remains unknown. The most commonly cited cause is a decrease 110 
in systemic concentrations of endogenous benzodiazepines/benzodiazepine-like substances 111 
from the portal circulation following shunt attenuation.26 Other suggested causes include 112 
hypoglycemia, hepatic encephalopathy, hypoxemia/hypoxic brain injury, systemic 113 
hypertension, electrolyte disturbances, and concurrent brain disease.2,3,17,18,21 None of these; 114 
however, has been consistently identified in affected dogs.1-3,6-11,15,17,18,21,22 Anecdotally, 115 
prolonged surgical and anesthetic times, and intraoperative hypotension, have been suggested 116 
to be implicated in PAS; however, these are not supported by results of a recent study.6  117 
 118 
Risk factors for development of PAS are not well established.7 Development of seizures has 119 
not been prevented by partial ligation,1-3,9,12,20,21 use of delayed attenuation devices,3-120 
5,10,12,14,15,17,22,23 or coil embolization.24,25 In a recent study, increasing age and the presence of 121 
hepatic encephalopathy (HE) immediately preoperatively were identified as risk factors for 122 
development of post-attenuation neurologic signs (PANS) and PAS.7 Matushek et al reported 123 
that 40% of dogs that developed PAS had a history of preoperative HE.1 In a study by Tisdall 124 
et al,3 dogs with cEHPSSs were significantly more likely to develop PANS than dogs with 125 
cIHPSSs; however, this is not supported by two more recent studies.7,14 In the study by Tisdall 126 
et al,3 there was also a trend towards dogs with portoazygous shunts being at greater risk of 127 
PANS than those with other shunt morphologies. Certain breeds have been suggested to be at 128 
increased risk of PANS/PAS including Pugs,3,10,17 Jack Russell terriers,14 and Maltese terriers.9 129 
 130 
Efforts to reduce the incidence of PAS in dogs undergoing cEHPSS attenuation have included 131 
pre-treatment with phenobarbital,3,10,15 potassium bromide,4,23 and levetiracetam (LEV).5-7 In 132 
one study,3 no dog that received prophylactic phenobarbital experienced postoperative 133 
generalized seizures; however, the overall incidence of PANS was not significantly decreased. 134 
Development of seizures has also been described following pre-treatment with potassium 135 
bromide.4,23 There are conflicting reports in the literature regarding the possible protective 136 
effects of LEV against development of PAS.5-7 Results of a retrospective study in 2011 led to 137 
a paradigm shift in the preoperative management of dogs undergoing shunt attenuation in many 138 
institutions.5 In that study,5 no dog that received LEV at 20mg/kg every eight hours (TID) for 139 
a minimum of 24 hours preoperatively experienced PAS. Conversely, 5% of dogs that did not 140 
receive LEV pre-treatment experienced PAS leading to a decision for humane euthanasia.5 141 
These results; however, are not supported by two more recent studies,6,7 wherein pre-treatment 142 
with LEV was not associated with reduced incidence of PAS. Therefore, the objectives of this 143 
study were to report the (1) incidence of PAS in a large cohort of dogs that underwent cEHPSS 144 
attenuation and (2) compare incidence of PAS in dogs that either did or did not receive 145 
prophylactic LEV. Our hypothesis was that there would be no significant difference in 146 
incidence of PAS among dogs that either did or did not receive prophylactic LEV.   147 
Materials and Methods 148 
Inclusion and exclusion criteria 149 
Medical records at ten veterinary institutions were retrospectively reviewed to identify dogs 150 
that underwent surgical attenuation (suture ligation [SL], thin film banding [TFB], or ameroid 151 
ring constrictor [ARC] placement) of a single cEHPSS from January 2005 through July 2017. 152 
Additionally, two of the authors (RNW, KMP) performed surgery at more than one institution 153 
during the study period. All cEHPSSs operated by these two surgeons during this timeframe 154 
were reviewed and incidence of PAS was calculated on an individual rather than institutional 155 
basis. Exclusion criteria included cIHPSSs; multiple cEHPSSs; cEHPSSs with apparent portal 156 
vein aplasia that precluded shunt attenuation; pre-treatment with anti-seizure medication(s) 157 
other than LEV within one month prior to surgery; dogs that died or were euthanized within 158 
24 hours postoperatively for reasons unrelated to seizure activity; dogs that received LEV 159 
preoperatively but did not have it continued postoperatively, dogs that received LEV 160 
postoperatively only; and dogs with incomplete medical records to permit stratification into the 161 
appropriate group. Institutions that biased administration of LEV towards dogs perceived to be 162 
at greater risk of PAS were not included in this study. Post-attenuation seizures were defined 163 
as those that occurred within seven days postoperatively. Dogs that experienced onset of 164 
seizure activity after seven days were recorded as not having developed PAS. 165 
 166 
Data collection 167 
All dogs 168 
Each contributing institution/surgeon assigned all dogs that satisfied the inclusion criteria to 169 
one of three groups:  170 
Group LEV-: Dogs that received no anti-seizure prophylaxis. 171 
Group LEV1: Dogs that received LEV at >15mg/kg TID for >24 hours preoperatively or a 172 
60mg/kg intravenous loading dose of LEV perioperatively, with continuation of LEV 173 
postoperatively at >15mg/kg TID.  174 
Group LEV2: Dogs that received LEV at <15mg/kg TID, for <24 hours preoperatively, or 175 
continued at <15mg/kg TID postoperatively. 176 
 177 
Dogs that received less than TID administration of LEV (regardless of accompanying dose) 178 
were assigned to group LEV2. Postoperative duration of LEV was also recorded for all dogs 179 
in groups LEV1 and LEV2.  180 
 181 
Dogs that developed post-attenuation seizures 182 
Additional data retrieved only from the medical record of dogs that developed PAS within 183 
seven days postoperatively and compared between groups of affected dogs included breed, age, 184 
sex/neuter status, and body-weight at time of surgery; shunt morphology (portocaval, 185 
portoazygous or portophrenic); concurrent/historical conditions at presentation; presence of 186 
preoperative neurologic signs; presence of preoperative seizures; method of shunt 187 
identification (abdominal ultrasound, computed tomography angiography [CTA], scintigraphy, 188 
intraoperative portovenography [IOPV], magnetic resonance imaging [MRI]); details of 189 
preoperative medical management (diet, antimicrobial, lactulose); method of shunt attenuation 190 
(SL, TFB, ARC) and degree of acute intraoperative attenuation (none, partial, or 191 
complete); type and timing of PAS; and electrolyte (sodium, potassium and chloride), glucose 192 
and ammonia concentrations around the time of PAS occurrence (where available). Dogs that 193 
received preoperative antimicrobial and lactulose medication were recorded as either having 194 
received these medications for a minimum of one week prior to surgery, or not. In cases where 195 
prophylactic LEV was administered, timing of last preoperative dose in relation to 196 
commencement of surgery, and most recently administered dose relative to seizure onset (in 197 
hours) was recorded. Timing of occurrence of seizures was recorded in hours where available 198 
or converted to hours if recorded in days. Dogs were stratified as having experienced 199 
partial/focal seizures only, or generalized seizures with or without partial/focal seizures. For 200 
dogs that developed PAS, short-term survival, defined as survival to 30 days, was also 201 
recorded. 202 
 203 
Statistical analyses 204 
Continuous variables were tested for normality using the Shapiro-Wilk test. Normally 205 
distributed continuous data were presented as mean and standard deviation. Non-normally 206 
distributed continuous data were presented as median and range. Categorical variables were 207 
presented as frequency and percentages (with 95% confidence intervals [CI]). Normally 208 
distributed continuous data were compared between groups of dogs that experienced PAS 209 
using One-Way ANOVA. Non-normally distributed continuous data were compared using 210 
the Kruskal-Wallis and Mann-Whitney U tests, while categorical variables were compared 211 
between PAS groups using Pearson’s Chi-Squared test. A power analysis was performed 212 
based on a modification of previously published data.5 In that study,5 dogs that did or did not 213 
receive pre-treatment with LEV had a 0% and 5% incidence of PAS, respectively. Using an 214 
incidence of 1% and 5%, respectively, a total of 284 dogs per group would be required to 215 
show a true difference between two groups if it were to exist, with a power of 80% and an 216 
alpha of 0.05. P values < 0.05 were considered significant. Statistical analyses were 217 
performed using commercially available softwarea.  218 
  219 
Results 220 
A total of 940 dogs satisfied the inclusion criteria and were included in the study. Of these, 75 221 
(8.0%;CI:6.4-9.9%) dogs developed PAS. Details of three dogs were partially reported 222 
previously.15,16 Incidence of PAS within individual institutions is listed in Table 1. 223 
Group LEV- (no anti-seizure prophylaxis) 224 
Five-hundred-and-twenty-three dogs were included in group LEV-; 35 (6.7%;CI:4.9-9.2%) 225 
developed PAS.  226 
Group LEV1 (>15mg/kg TID for >24 hours preoperatively or a 60mg/kg intravenous 227 
loading dose of LEV perioperatively, with continuation of LEV postoperatively at 228 
>15mg/kg TID) 229 
One-hundred-and-eighty-eight dogs were included in group LEV1; 21 (11.2%;CI:7.4-16.5%) 230 
developed PAS. All 21 dogs were still receiving LEV at the time of PAS occurrence. Median 231 
(range) postoperative duration of LEV of 167 dogs in group LEV1 that did not develop PAS 232 
was ten (1-760) days; recorded as indefinitely (n=1), not recorded (n=2). Of those that 233 
developed PAS (n=21), median (range) duration of pre-treatment (excluding two dogs that 234 
received a 60mg/kg intravenous loading dose perioperatively) was six (1-237) days; median 235 
(range) preoperative dose was 20mg/kg (15-60mg/kg [76.2% dogs received >20mg/kg]); all 236 
received TID administration of LEV pre- and postoperatively (excluding two dogs that 237 
received a 60mg/kg intravenous loading dose perioperatively); and median (range) 238 
postoperative dose was 20mg/kg TID (15-23mg/kg [85.7% dogs received >20mg/kg]). 239 
Group LEV2 (<15mg/kg TID, for <24 hours preoperatively, or continued at <15mg/kg 240 
TID postoperatively) 241 
Two-hundred-and-twenty-nine dogs were included in group LEV2; 19 (8.3%;CI:5.4-12.6%) 242 
developed PAS. All 19 dogs were still receiving LEV at the time of PAS occurrence. Median 243 
(range) postoperative duration of LEV administration of 209 dogs in group LEV2 that did not 244 
develop PAS was seven (2-66) days; not recorded (n=3). Of those that developed PAS (n=19), 245 
median (range) duration of pre-treatment was 72 hours (12.7 hours-97 days), with two 246 
additional dogs recorded as having commenced LEV treatment perioperatively (n=1; 20mg/kg, 247 
and continued at 20mg/kg TID postoperatively) or intraoperatively (n=1; 60mg/kg loading 248 
dose but continued at 19.23mg/kg BID postoperatively); median (range) preoperative dose was 249 
20mg/kg (10-20mg/kg); ten received TID administration preoperatively, six dogs received BID 250 
administration, while three received a single dose preoperatively (two 251 
perioperatively/intraoperatively and one 12.6 hours preoperatively); median (range) 252 
postoperative dose was 20mg/kg (10-20mg/kg); 13 dogs received TID administration 253 
postoperatively, while the remaining 6 dogs received BID administration. 254 
 255 
No significant difference in incidence of PAS between groups was identified (p=0.14). No 256 
significant differences between groups of dogs that seized with respect to variables 257 
investigated were identified (Table 2).  258 
 259 
Demographics of dogs that developed post-attenuation seizures (n=75) 260 
The most common breeds were mixed breed (n=16), Bichon Frise (n=10), Yorkshire terrier 261 
(n=9), Shih Tzu (n=8), and Pug (n=8). Median (range) age was 34 (4-115) months. There 262 
were 25 neutered males, 22 spayed females, 13 sexually-intact males, 13 sexually-intact 263 
females, and two unspecified females. Median (range) weight was 6.2 kg (2.0-21.0 kg).  264 
 265 
Method of shunt identification and shunt morphology of dogs that developed post-266 
attenuation seizures (n=75) 267 
Method of shunt identification included abdominal ultrasound (n=61;81.3%), CTA 268 
(n=21;28.0%), IOPV (n=17;22.7%), scintigraphy (n=1;1.3%), and MRI (n=1;1.3%). 269 
Information regarding shunt morphology was available for 73/75 (97.3%) dogs. Overall, shunt 270 
types included portocaval (n=53), portoazygous (n=13) and portophrenic (n=7).  271 
 272 
Concurrent/historical conditions at presentation in dogs that developed post-attenuation 273 
seizures (n=75) 274 
Concurrent/historical conditions were recorded in 25/75 (33.3%) dogs and most commonly 275 
included urolithiasis (n=17), urinary tract infection (n=6), and cardiac murmur (n=3). Two dogs 276 
had previously undergone cEHPSS attenuation but did not develop PAS following initial 277 
surgery.  278 
 279 
Incidence of preoperative neurologic signs and seizures in dogs that developed post-280 
attenuation seizures (n=75) 281 
Preoperative neurologic signs were recorded in 61/75 (81.3%) dogs and most commonly 282 
included lethargy (n=28), pacing/compulsive walking (n=12), dullness (n=10), head pressing 283 
(n=10), ataxia (n=10), abnormal/change in behavior (n=10), hypersalivation/drooling (n=9), 284 
circling (n=5), (possible) blindness (n=4), disorientation (n=4), sleepy/inappropriate 285 
sleeping/sleeps a lot (n=4), depression (n=4), and two each of twitching, weakness, and 286 
restlessness. Preoperative seizures were recorded in 11/75 (14.7%) dogs.  287 
 288 
Details of preoperative medical management of dogs that developed post-attenuation 289 
seizures (n=75) 290 
Information regarding preoperative medical management was available for 74/75 (98.7%) 291 
dogs. One dog (group LEV2) was prescribed hepatic diet, an antimicrobial and lactulose but it 292 
could not be confirmed if this occurred. Overall, 48/75 (64.0%) dogs received a prescription 293 
hepatic diet; eight (10.7%) received an unspecified protein restricted diet; three (4.0%) received 294 
a prescription hypoallergenic diet; two (2.7%) received an unspecified vegetarian diet; and four 295 
dogs received one each of protein restricted renal diet, prescription gastrointestinal diet, 296 
homemade protein restricted diet, and chicken and vegetables. Sixty-six (88.0%) dogs received 297 
a minimum of seven days of preoperative antimicrobial, while 68 (90.7%) received a minimum 298 
of 7 days of preoperative lactulose.  299 
 300 
Method and degree of acute intraoperative shunt attenuation in dogs that developed post-301 
attenuation seizures (n=75) 302 
Shunts were attenuated using TFB (n=30; 40.0%), SL (n=23; 30.7%), ARC (n=21; 28.0%), or 303 
a combination of SL and TFB (n=1; 1.3%).  304 
 305 
Type and timing of post-attenuation seizures 306 
Sixty-two (82.7%) dogs experienced generalized PAS, while the remaining 13 (17.3%) dogs 307 
experienced focal PAS only. Onset of seizure activity (focal or generalized; whichever 308 
occurred first) occurred after a median (range) of 48 (8-128) hours.  309 
 310 
Clinicopathologic variables at time of seizures (Table 2) 311 
Sodium, potassium and chloride  312 
Sodium and potassium concentrations at the time of seizures were available for review in 31/75 313 
(41.3%) dogs and recorded as normal in a further three dogs. Sodium and potassium 314 
concentrations were available for 14/35 (40%), 5/21 (23.8%), and 12/19 (63.2%) dogs in 315 
groups LEV-. LEV1 and LEV2, respectively. Chloride concentration was available for review 316 
in 22/75 (29.3%) PAS dogs, recorded as normal in two dogs and high in a further one dog. 317 
Chloride concentration was available for 10/35 (28.6%), 4/21 (19.0%) and 8/19 (42.1%) dogs 318 
in groups LEV-, LEV1 and LEV2, respectively.  319 
Ammonia and glucose 320 
Ammonia concentration was available for review in 30/75 (40.0%) dogs, recorded as within 321 
normal limits for four (5.3%) and high for a further dog (1.3%). Overall, 76.7% of values were 322 
<70.0 µmol/l. Ammonia concentration was available for 9/35 (25.7%), 10/21 (47.6%) and 323 
11/19 (57.9%) dogs in groups LEV-, LEV1 and LEV2, respectively. Glucose concentration 324 
was available for 36/75 (48.0%) dogs and recorded as normal for a further two dogs. Overall, 325 
34/37 (91.9%) values were >3.3 mmol/l. Glucose concentration was available for 14/35 (40%), 326 
7/21 (33.3%) and 15/19 (78.9%) dogs in groups LEV-, LEV1 and LEV2, respectively.  327 
 328 
Timing of last preoperative dose of LEV in relation to surgery 329 
Timing of last preoperative dose of LEV in relation to surgery was available for 9/21 (42.9%) 330 
dogs in group LEV1 and 7/19 (36.8%) dogs in group LEV2. In addition, timing of last 331 
preoperative dose was recorded as perioperative in 7/21 (33.3%) dogs in group LEV1 and 6/19 332 
(31.6%) dogs in group LEV2. One additional dog in group LEV2 received the last preoperative 333 
dose of LEV the previous day.  334 
 335 
Timing of last (most recent) dose of LEV relative to seizure onset 336 
Timing of last dose of LEV in relation to seizure onset was available for 16/40 (40.0%) dogs; 337 
5 (23.8%) dogs in group LEV1 and 11 (57.9%) dogs in group LEV2 (Table 2).  338 
 339 
Short-term survival of dogs that developed PAS 340 
Overall, 23/75 (30.7%) dogs survived to 30 days postoperatively.  341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
349 
Discussion 350 
The main findings of this study are: (1) the overall incidence of PAS was low (8%) and similar 351 
to that reported in recent literature,6,7 and (2) prophylactic treatment with LEV, at either 352 
>15mg/kg TID for >24 hours preoperatively or a 60mg/kg intravenous loading dose 353 
perioperatively, with continuation postoperatively at >15mg/kg TID (group LEV1), or other 354 
less standardized LEV protocols (LEV2), did not result in a reduced incidence of PAS 355 
compared to dogs that did not receive any prophylactic LEV (group LEV-). No significant 356 
differences between groups of dogs that seized with respect to signalment; shunt morphology; 357 
concurrent conditions; incidence of preoperative neurologic signs and seizures; preoperative 358 
medical management; method and degree of shunt attenuation; timing of and type of PAS; 359 
electrolyte, ammonia and glucose concentrations at the time of seizures, and short-term 360 
survival were identified. The results of this study corroborate findings of two recent studies6,7 361 
that prophylactic treatment with LEV does not afford protection against development of PAS 362 
in contrast to what has been suggested by Fryer et al.5  363 
 364 
In a pharmacokinetic study by Moore et al,27 administration of LEV at ~20mg/kg TID 365 
consistently produced plasma LEV concentrations within the 5-45 µg/ml therapeutic range in 366 
healthy dogs. This therapeutic range is based on extrapolations from humans and the plasma 367 
LEV concentrations required to prevent seizures in dogs undergoing cEHPSS attenuation is 368 
unknown. In our study, we included dogs that received LEV at >15mg/kg TID in group LEV1 369 
to accommodate for expected small deviations from the recommended 20mg/kg dose due to 370 
tablet size limitations. The median preoperative dose of LEV in dogs that developed PAS in 371 
group LEV1 was 20mg/kg, with over 75% of dogs receiving >20mg/kg TID pre- and 372 
postoperatively. In the study by Moore et al,27 mean terminal half-life of LEV was 3.6 hours, 373 
which resulted in steady-state after 18 hours (Moore et al, personal communication). These 374 
pharmacokinetic data support that steady-state should have been achieved at the time of surgery 375 
in dogs in group LEV1 in our study. Furthermore, these data would suggest that there is no 376 
benefit in pre-treating dogs for >24 hours prior to surgery. We also included in group LEV1 377 
dogs that received a 60mg/kg intravenous loading dose of LEV perioperatively. Based on a 378 
pharmacokinetic study,28 administration of a single intravenous 60mg/kg loading dose resulted 379 
in plasma LEV concentrations within or above the recommended therapeutic range for at least 380 
8 hours. This was followed with postoperative administration of LEV at >15mg/kg TID in such 381 
dogs in our study. We did not include in our study dogs that received other anti-seizure 382 
medication concurrently with LEV due to expected alterations in the pharmacokinetics of 383 
LEV.29,30  384 
 385 
The median age (34 months) of dogs that developed PAS in our study was greater than the 386 
expected age of dogs undergoing cEHPSS attenuation.31 This observation that older dogs may 387 
be at increased risk of experiencing PANS/PAS has been made by several other investigators.1-388 
4,7,17 In a recent study by Strickland et al, increasing age was found to be a significant risk factor 389 
for development of PANS and PAS.7  390 
 391 
Postoperative administration of LEV in our study was very variable, reflecting its multicenter 392 
nature, with similar variation reported in the literature.5-7 In a recent study by Strickland et al, 393 
all dogs that were administered LEV received the drug for a minimum of five days 394 
postoperatively.7 In the study by Fryer et al,5 median postoperative duration of LEV was 33 395 
days; however, some dogs appear not to have received any postoperative LEV, with the authors 396 
placing emphasis on pre-treatment of dogs. Similarly, in the study by Brunson et al,6 the authors 397 
do not specifically report postoperative duration of LEV. Based on pharmacokinetic data by 398 
Moore et al, dogs that do not have administration of LEV continued postoperatively would be 399 
expected to have drug plasma concentrations fall below the recommended therapeutic range 400 
after approximately 12 hours.27 In our study, all dogs that developed PAS in groups LEV1 and 401 
LEV2 were still receiving LEV at the time of seizure occurrence. We acknowledge that there 402 
is an important reliance on owners to administer anti-seizure medication(s) at home. We 403 
defined PAS as seizures that occurred within seven days postoperatively in accordance with 404 
what has been reported in the literature.1-25 Occurrence of seizures was recorded up to 128 405 
hours postoperatively in our study. It would therefore seem intuitive, if considering 406 
prophylactically treating dogs with LEV, to continue postoperative administration for a 407 
minimum of six days.  408 
 409 
In the current study, we did not exclude dogs that developed PAS that had a history of 410 
preoperative seizures. In a recent study by Brunson et al,6 dogs with a history of preoperative 411 
seizure activity that subsequently developed PAS had a significantly increased probability of 412 
survival compared to those that had not. It is possible that both subsets did not experience 413 
seizures of the same etiopathogenesis, although this is purely speculative. It is also possible 414 
that some dogs that had a history of preoperative seizures had continuation of these seizures 415 
postoperatively. Dogs that had a history of preoperative neurologic signs were also not 416 
excluded in our study. Strickland et al reported the presence of HE immediately preoperatively 417 
a risk factor for development of PANS and PAS.7 In a study by Matushek et al, 40% of dogs 418 
that experienced PAS had a history of preoperative HE.1 We also did not exclude dogs in whom 419 
hypoglycemia, hyperammonemia, or electrolyte derangements were identified at the time of 420 
PAS occurrence. While it is possible that some dogs may have experienced seizures directly 421 
attributable to these disturbances, we suspected that there would be an even distribution of such 422 
cases across all three groups, which was subsequently confirmed by statistical comparisons. 423 
None of these derangements have consistently been identified within or among previous 424 
studies,1-6,8-11,15,17,21,22 nor has correction of such abnormalities been found to abolish seizure 425 
activity in all cases.1-4 Seizures have also been demonstrated to occur in the face of ammonia 426 
concentrations lower than those obtained preoperatively,1,2,11 and at glucose concentrations, 427 
albeit decreased, not typically associated with seizure activity.2,4 Unfortunately, these 428 
clinicopathologic variables were not available for review for all dogs in our study, which may 429 
have led to underestimation of the incidence of these derangements overall and within 430 
individual PAS groups.  431 
 432 
We acknowledge a number of important limitations in this study. This was a retrospective 433 
study, wherein accuracy of recorded data depends on accuracy and completeness of the medical 434 
records. Details concerning variables other than administration of LEV were not available for 435 
all 940 dogs in this study and it is possible that a confounding factor may have biased one or 436 
more groups towards a higher rate of PAS. This study did not include institutions that biased 437 
administration of LEV towards dogs perceived to be at greater risk of PAS (eg, older dogs or 438 
those that had a history of preoperative neurologic signs or seizures). Therefore, the authors 439 
speculate that a homogenous population of dogs exists overall within the three groups. 440 
Moreover, if it were the case that the LEV groups are in fact biased towards a higher proportion 441 
of at risk dogs, these are the dogs clinicians would be expected to select for prophylactic 442 
treatment with LEV; however, 8.3-11.2% of these treated dogs continued to develop PAS in 443 
our study. Owing to the non-prospective nature of this study, administration of LEV within 444 
individual institutions was not randomized, with the decision to pre-treat with LEV based on 445 
the attending clinician’s belief regarding its possible protective effects against development of 446 
PAS. All dogs that developed PAS in groups LEV1 and LEV2 were still receiving LEV at the 447 
time of seizure occurrence; however, exact timing of last dose relative to seizure onset could 448 
not be verified in all cases. If this were greater than the recommended 8-hour dosing interval, 449 
PAS may have developed due to inadequate plasma LEV concentrations rather than a lack of 450 
efficacy of the drug. Based on a modification of results of Fryer et al,5 a power analysis 451 
indicated that 284 dogs would be required in groups LEV- and LEV1 to show a true difference 452 
in incidence of PAS if it were to exist. Due to administration of less standardized LEV protocols 453 
(group LEV2) within institutions in our study, a total of only 188 dogs met the inclusion criteria 454 
for group LEV1. It is possible that this shortfall may have resulted in a type II error in our study 455 
and that a small difference does exist between groups but could not be detected. Further 456 
prospective randomized studies are required to confirm our results. The incidence of PAS in 457 
group LEV1 was almost twice that in group LEV- and it is possible that this is reflective of the 458 
relatively smaller number of dogs in group LEV1. Measurement of plasma LEV concentrations 459 
was not performed in our study and is not routinely performed in clinical practice. We excluded 460 
dogs that died or were euthanized within 24 hours postoperatively for reasons unrelated to 461 
seizure activity. Ideally, this would have been extended to at least five days; however, several 462 
dogs were discharged prior to five days postoperatively following an uncomplicated recovery 463 
and we could not guarantee that they did not die of other causes within this timeframe and thus 464 
were not given the opportunity to develop PAS. Due to its retrospective nature, the 465 
categorization of seizure type as focal or generalized in this study reflects what was recorded 466 
in the medical record. Serum electrolyte, ammonia and glucose concentrations were not 467 
available for review for all dogs in this study, which will affect the results of our study. 468 
Furthermore, due to its multicenter nature, where clinicopathologic variables were available, 469 
they were obtained from several different analyzers. Finally, we acknowledge the subjectivity 470 
in assessing the degree shunt attenuation intraoperatively, particularly concerning partial 471 
attenuation. 472 
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 608 
 609 
 610 
Institution/Group LEV- LEV1 LEV2 
1 2/114 (1.8%)  - 3/41 (7.3%) 
2* 5/59 (8.5%)  3/18 (16.7%)  0/24 (0.0%)  
3 1/17 (5.9%)  1/18 (5.6%) 1/12 (8.3%) 
4 6/161 (3.7%) - - 
5 1/19 (5.3%) 2/31 (6.5%) 1/17 (5.9%) 
6 4/40 (10.0%) 2/14 (14.3%) 2/7 (28.6%) 
7 1/6 (16.7%) 1/10 (10.0%) - 
8 - 4/24 (16.7%) 5/20 (25.0%) 
9 0/12 (0.0%) 5/59 (8.5%) 0/25 (0.0%) 
10 4/34 (11.8%) 3/7 (42.9%) 5/43 (11.6%) 
11 5/32 (15.6%) 0/7 (0.0%) 1/11 (9.1%) 
12* 6/30 (20.0%) - 1/28 (3.6%) 
Total number of 
dogs 524 188 228 
Number of dogs 
that developed 
PAS 35 21 19 
Incidence of PAS 
(%, 95% CI)  
6.7% (CI: 
4.9-9.2%) 
11.2% (CI: 7.4-
16.5%) 
8.3% (CI:5.4-
12.6%) 
Table 1: Incidence of post-attenuation seizures among 940 dogs that underwent single cEHPSS 611 
attenuation.  612 
*EHPSSs operated by an individual surgeon rather than institution.  613 
 614 
Group/Variable LEV- LEV1 LEV2 P-
valu
e 
Breed § Mixed breed 
(n=7) 
§ Bichon Frise 
(n=7) 
§ Yorkshire 
terrier (n=6) 
§ Shih Tzu 
(n=5) 
§ Maltese 
terrier (n=4) 
§ Pug (n=4) 
§ Miniature 
Schnauzer 
(n=1) 
§ Jack Russell 
terrier (n=1) 
§ Mixed breed 
(n=4) 
§ Yorkshire 
terrier (n=3) 
§ Shih Tzu 
(n=3) 
§ Chihuahua 
(n=3) 
§ Pug (n=2) 
§ Maltese terrier 
(n=1) 
§ Miniature 
Schnauzer 
(n=1) 
§ Jack Russell 
terrier (n=1) 
§ Dachshund 
(n=1) 
§ Norfolk terrier 
(n=1) 
§ Border terrier 
(n=1) 
§ Mixed breed 
(n=5) 
§ Bichon Frise 
(n=3) 
§ Jack Russell 
terrier (n=3) 
§ Pug (n=2) 
§ Dachshund 
(n=2) 
§ Maltese terrier 
(n=1) 
§ West Highland 
White terrier 
(n=1) 
§ Brussels 
Griffon (n=1) 
§ Setter (n=1) 
0.06 
Age 
Median (range) 
35 (4-115) 
months 
34 (6-59) months 35 (8-105) months 0.68 
Sex/neuter status § Male intact 
(n=7) 
§ Male 
neutered 
(n=13) 
§ Female 
intact (n=6) 
§ Female 
spayed (n=7) 
§ Unspecified 
female (n=2) 
§ Male intact 
(n=5) 
§ Male neutered 
(n=4) 
§ Female intact 
(n=3) 
§ Female spayed 
(n=9) 
§ Male intact 
(n=1) 
§ Male neutered 
(n=8) 
§ Female intact 
(n=4) 
§ Female spayed 
(n=6) 
0.34 
Weight 
Median (range) 
 
6.8 (2.2-11.9) kg 6.0 (2.0-13.6) kg 6.5 (4.2-21.0) kg 0.46 
Shunt morphology § Portocaval 
(n=26) 
§ Portoazygou
s (n=5) 
§ Portophrenic 
(n=3) 
§ Portocaval 
(n=14) 
§ Portoazygous 
(n=4) 
§ Portophrenic 
(n=2) 
§ Portocaval 
(n=13) 
§ Portoazygous 
(n=4) 
§ Portophrenic 
(n=2) 
0.97 
Presence of 
concurrent/historica
9/35 (25.7%) 10/21 (47.6%) 6/19 (31.6%) 0.24 
l conditions at 
presentation  
Presence of 
preoperative 
neurologic signs 
29/35 (82.9%) 16/21 (76.2%) 16/19 (84.2%) 0.77 
Presence of 
preoperative 
seizures 
4/35 (11.4%) 
 
5/21 (23.8%) 
 
2/19 (10.5%)  0.38 
Preoperative diet § Hepatic diet 
(n=23) 
§ Unspecified 
protein-
restricted 
diet (n=3) 
§ Protein-
restricted 
renal diet 
(n=1) 
§ Other diet 
(n=2) 
§ Hepatic diet 
(n=14) 
§ Unspecified 
protein-
restricted diet 
(n=4) 
§ Hypoallergeni
c diet (n=1) 
§ Vegetarian 
diet (n=1) 
§ Hepatic diet 
(n=11) 
§ Unspecified 
protein-
restricted diet 
(n=1) 
§ Hypoallergenic 
diet (n=2) 
§ Gastrointestina
l diet (n=1) 
§ Vegetarian diet 
(n=1) 
0.47 
Minimum of 7 days 
of preoperative 
antimicrobial(s) 
33/35 (94.3%) 19/21 (90.5%) 14/18 (77.8%) 0.18 
Minimum of 7 days 
of preoperative 
lactulose 
34/35 (97.1%) 19/21 (90.5%) 15/18 (83.3%) 0.21 
(i) Method and (ii) 
degree of acute 
intraoperative shunt 
attenuation 
SL (n=13) 
§ Complete 
ligation 
(n=11)  
§ Partial 
ligation 
(n=2)  
TFB (n=11)  
§ No 
attenuation 
(n=1) 
§ Partial 
attenuation 
(n=10) 
ARC (n=10) 
§ No 
attenuation 
(n=10)  
Combination of 
SL and TFB 
(n=1) 
§ Partial 
attenuation 
(n=1)  
TFB (n=9) 
§ No attenuation 
(n=5) 
§ Partial 
attenuation 
(n=4) 
ARC (n=8)  
§ No attenuation 
(n=8)  
SL (n=4)  
§ Complete 
ligation (n=4)	
TFB (n=10)  
§ No attenuation 
(n=6)  
§ Partial 
attenuation 
(n=4) 
SL (n=6) 
§ Complete 
ligation (n=5) 
§ Partial ligation 
(n=1)  
ARC (n=3) 
§ No attenuation 
(n=3) 
(i) 
0.45 
(ii) 
0.27 
Type of post-
attenuation seizures 
§ 28/35 
(80.0%) 
generalized 
PAS 
§ 7/35 (20.0%) 
focal PAS 
only 
§ 17/21 (81.0%) 
generalized 
PAS 
§ 4/21 (19.0%) 
focal PAS 
only 
§ 17/19 (89.5%) 
generalized 
PAS 
§ 2/19 (10.5%) 
focal PAS only 
0.66 
Onset of seizure 
activity  
Median (range) 
hours  
60 (8-120)  
 
60 (17-128)  47 (20-120) 0.06 
Sodium (n=31) 
Median (range) 
mmol/l 
143.0 (135.1-
171.0)  
148.0 (142.5-
155.0)  
144.0 (138.3-
150.3)  
0.24 
Potassium (n=31) 
Mean (+ SD) mmol/l 
4.1 (+0.6)  3.7 (+0.6)  4.1 (+0.3)  0.37 
Chloride (n=22) 
Mean (+ SD) mmol/l 
114.6 (+6.7)  112.5 (+ 5.8)  117.4 (+7.5)  0.49 
Ammonia (n=30) 
Median (range) 
µmol/l 
39 (8.0-72.6)  37.1 (0.0-104.0)  25 (2.0-261.6) 0.84 
Glucose (n=36) 
Median (range) 
mmol/l 
4.9 (2.4-7.2)  5.3 (3.6-6.4)  5.5 (1.1-6.3)  0.56 
Timing of last 
preoperative dose of 
LEV in relation to 
surgery (n=16) 
Median (range) 
minutes 
- 240 (80-480)  
 
180 (95-750)  
§ >480 
minutes 
(750 
minutes) 
(n=1) 
 
0.54 
Timing of last (most 
recent) dose of LEV 
relative to seizure 
onset (n=16) 
Mean (+ SD) 
minutes 
- 383.8 (+52.7)  278.2 (+162.5) 
§ >480 
minutes 
(530 
minutes) 
(n=1) 
 
0.07 
Short-term survival 14/35 (40%) 6/19 (31.6%) 3/19 (15.8%) 0.19 
 615 
Table 2: Comparison of variables between groups of dogs that developed PAS.  616 
Abbreviations: PAS; post-attenuation seizures, SL; suture ligation, ARC; ameroid ring 617 
constrictor, TFB; thin-film banding, LEV; levetiracetam, SD; standard deviation. 618 
